IMCD publishes convocation for its upcoming Annual General Meeting
ROTTERDAM, The Netherlands (15 March 2023) – IMCD N.V. (“IMCD” or “Company”), a leading distributor of speciality chemicals and ingredients, today published the convocation and agenda for its annual general Meeting of shareholders (AGM), which will be held on Wednesday 26 April 2023 at 10:30 a.m. CET at the Mainport by Inntel Hotel, Schiedamsedijk 140, 3011 EN, in Rotterdam, the Netherlands.
The convocation, agenda and further documentation for the AGM are available in the Investors’ section of IMCD’s website. The meeting will be held in person.
The agenda for the AGM includes, amongst other, the nomination of Valerie Diele-Braun as Member of the Management Board and successor of Piet van der Slikke as IMCD’s CEO as of 1 January 2024. This nomination was announced with a separate press release at the date hereof, available here.
Other proposals include the reappointment of Deloitte Accountants B.V. as external auditor for the fiscal year 2024, and appointment of Ernst & Young Accountants LLP as external auditor as of the fiscal year 2025. Full details of all voting items are included in the proxy materials published on the website. The materials include the 2022 Annual Report as published on 24 February 2023, which hold the financial statements, the reports of the Management Board and Supervisory Board and the 2022 Remuneration Report.
Subject to adoption by the AGM of the dividend proposal of EUR 6.78 per share in cash, the dividend calendar will be as follows:
- 26 April 2023 - AGM | Dividend announcement
- 28 April 2023 - Ex-dividend date
- 2 May 2023 - Dividend record date
- 4 May 2023 - Dividend payment date
Shareholders are advised to check the information on the website regularly for any updates.
This press release contains information that qualifies as inside information within the meaning of Article 7(1) of the EU Market Abuse Regulation and was issued on 15 March 2023, 07:00 a.m. CET.
Attached, please find the full press release in pdf format.
Attachment
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
Årsrapport 202223.3.2023 22:58:17 CET | pressemeddelelse
Selskabsmeddelelse nr. 2 – 2023 København, den 23. marts 2023 Årsrapport 2022 Bestyrelsen i NTR Holding A/S har i dag behandlet og godkendt Selskabets årsrapport for regnskabsåret 2022. Årsrapporten har følgende hovedpunkter: NTR Holding koncernens salg af Daniamant A/S og Daniamant Ltd. blev gennemført den 31. januar 2022. Hovedparten af provenuet fra salget af Daniamant er udbetalt som udbytte. NTR Holding A/S har således i 2022 udbetalt udbytte på i alt DKK 49 pr. aktie, svarende til et samlet udbytte på DKK 121 mio. Bestyrelsen foreslår, at der ikke udloddes yderligere udbytte for 2022. Koncernens resultat af primær drift udviser et underskud på DKK 2,5 mio. (DKK -1,9 mio. i 2021), hvilket er i overensstemmelse med de senest udmeldte resultatforventninger. Koncernens totalindkomst udgør DKK 1,1 mio. Egenkapitalen udgør DKK 12,9 mio., svarende til en indre værdi pr. aktie på DKK 5,2. Bestyrelsen vil fortsat sondere NTR Holding A/S’ strategiske muligheder, herunder for at kapitaliser
Millicom (Tigo) announces a change in the Nomination Committee ahead of the 2023 Annual General Meeting23.3.2023 22:40:00 CET | Press release
Millicom (Tigo) announces a change in the Nomination Committee ahead of the 2023 Annual General Meeting Luxembourg, March 23, 2023 – The Nomination Committee of Millicom International Cellular S.A. (“Millicom”) announces that Mr. Nicolas Jaeger appointed by Atlas Luxco S.àr.l., has joined the Nomination Committee of Millicom. On March 17, 2023, Atlas Luxco S.àr.l. reported that it holds a 20% shareholding in Millicom. On March 23, 2023 Mr. Nicolas Jaeger joined the Nomination Committee. The Nomination Committee comprises Jan Dworsky, appointed by Swedbank Robur Funds; Viktor Kockberg, appointed by Nordea Investment Funds; Staley Cates, appointed by Southeastern Asset Management, Gerardo Zamorano appointed by Brandes Investment Partners, and Nicolas Jaeger appointed by Atlas Luxco S.àr.l., as well as the Chairman of Millicom’s Board of Directors, José Antonio Ríos García. Information about the work of the Nomination Committee can be found on Millicom’s website. Shareholders wishing to p
GreenMobility issues warrants23.3.2023 22:40:00 CET | Press release
Company Announcement no. 121– 2023 Copenhagen, March23rd, 2023 GreenMobility issues warrants The Board of Directors of GreenMobility A/S S (“GreenMobility” or the “Company”), has today resolved to grant warrants in the Company for the purpose of: Ensuring that shareholders, the Executive Management and other management employees of the Company have the same interests, and that everyone makes a special effort for the value creation in the Company and its subsidiaries.Retaining the Executive Management and management employees of the Company.Granting warrants to the Board of Directors as authorized at the 2021 Annual General Meeting but not yet granted Warrants granted will generally be subject to the existing warrant programs as publicized in company announcement no. 41 on November 19th, 2019 and in company announcement no. 64 on September 29th 2020 with certain deviations. The total issuance of warrants is in accordance with the resolutions passed at the Annual General Meetings held on
Inventiva announces the schedule of publication and presentation of its 2022 Full-Year Financial Results23.3.2023 22:00:00 CET | Press release
Daix (France), Long Island City (New York, United States), March 23, 2023 – Inventiva (Euronext Paris and Nasdaq: IVA) (the “Company”), a clinical-stage biopharmaceutical company focused on the development of oral small molecule therapies for the treatment of patients with non-alcoholic steatohepatitis (NASH) and other diseases with significant unmet medical needs, today announced that its management team will host a webcast to present the Company’s 2022 full-year financial results on Thursday, March 30, 2023. Inventiva’s 2022 full-year financial results will be published on Wednesday, March 29, 2023 at 4:00 pm (New York), 10:00 pm (Paris). Frédéric Cren, Chairman, CEO and cofounder of Inventiva, Pierre Broqua, Chief Scientific Officer and cofounder of Inventiva, Jean Volatier, Chief Financial Officer of Inventiva, and Michael Cooreman, Chief Medical Officer of Inventiva, will hold a conference call in English, followed by a Q&A session, onThursday, March 30, 2023, at8:00 am (New York)
Nyxoah Announces a $15 Million Private Placement Financing23.3.2023 21:05:00 CET | Press release
INSIDE INFORMATION REGULATED INFORMATION NyxoahAnnounces a $15 Million Private Placement Financing Mont-Saint-Guibert, Belgium – March 23, 2023, 9:05pm CET / 4:05pm ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced a €13.35 million private placement financing from the sale of 2,047,544 new ordinary shares at a price per share of €6.52 (approximately U.S. $7.10 at current exchange rates), the closing price on Euronext Brussels on March 23, 2023. Gross proceeds total €13.35 million (approximately U.S. $15 million at current exchange rates) and will be used for general corporate purposes. The closing is expected to occur on or about March 30, 2023, subject to customary closing conditions. The private placement financing includes historical Nyxoah shareholders, notably ResMed and Robert Taub, Nyxoah’s Founde